NO309090B1 - Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem - Google Patents
Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem Download PDFInfo
- Publication number
- NO309090B1 NO309090B1 NO962360A NO962360A NO309090B1 NO 309090 B1 NO309090 B1 NO 309090B1 NO 962360 A NO962360 A NO 962360A NO 962360 A NO962360 A NO 962360A NO 309090 B1 NO309090 B1 NO 309090B1
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- pyrrolidin
- acid
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000002475 indoles Chemical class 0.000 title description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 5
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 50
- 201000000980 schizophrenia Diseases 0.000 claims description 7
- 239000007858 starting material Substances 0.000 claims description 6
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 claims description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- -1 3-benzoylmethyl-pyrrolidin-1-yl Chemical group 0.000 abstract description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 abstract description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 abstract description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 125000004953 trihalomethyl group Chemical group 0.000 abstract 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000004452 microanalysis Methods 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 229960003878 haloperidol Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 9
- 229960004170 clozapine Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 208000009132 Catalepsy Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 206010047853 Waxy flexibility Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- ICNPOTSVAWPXRY-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-pyrrolidin-3-ylethanone Chemical compound C1=CC(F)=CC=C1C(=O)CC1CNCC1 ICNPOTSVAWPXRY-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- YLMRHBWFHJJKKX-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1H-indol-3-yl)propyl]pyrrolidin-3-yl]ethanone hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 YLMRHBWFHJJKKX-UHFFFAOYSA-N 0.000 description 3
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 101150013372 Htr2c gene Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- 229960004046 apomorphine Drugs 0.000 description 3
- 230000001484 cataleptigenic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 2
- XHCPPKSASMWCFC-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1h-indol-3-yl)ethyl]pyrrolidin-3-yl]ethanone;hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 XHCPPKSASMWCFC-UHFFFAOYSA-N 0.000 description 2
- WNOKNPQVKXNVFV-UHFFFAOYSA-N 3-(5-methoxy-1h-indol-3-yl)propan-1-ol Chemical compound COC1=CC=C2NC=C(CCCO)C2=C1 WNOKNPQVKXNVFV-UHFFFAOYSA-N 0.000 description 2
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 2
- COCNDHOPIHDTHK-UHFFFAOYSA-N 5-methoxyindole-3-acetic acid Chemical compound COC1=CC=C2NC=C(CC(O)=O)C2=C1 COCNDHOPIHDTHK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QJPOEAGOSMSFDO-UHFFFAOYSA-N Cl.C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 Chemical compound Cl.C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 QJPOEAGOSMSFDO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150104779 HTR2A gene Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BDRZTSIMFCSLGA-UHFFFAOYSA-N (4-fluorophenyl)-[1-[3-(5-methoxy-1H-indol-3-yl)propyl]piperidin-4-yl]methanone hydrochloride Chemical compound Cl.C12=CC(OC)=CC=C2NC=C1CCCN(CC1)CCC1C(=O)C1=CC=C(F)C=C1 BDRZTSIMFCSLGA-UHFFFAOYSA-N 0.000 description 1
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- DFFDCZLGTYJKKJ-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1-methylindol-3-yl)ethyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2N(C)C=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 DFFDCZLGTYJKKJ-UHFFFAOYSA-N 0.000 description 1
- KYJIQQZJLSVFGW-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[2-(5-methoxy-1h-indol-3-yl)ethyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2NC=C1CCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 KYJIQQZJLSVFGW-UHFFFAOYSA-N 0.000 description 1
- WCNJIZGUBYGBKT-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1-methylindol-3-yl)propyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2N(C)C=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 WCNJIZGUBYGBKT-UHFFFAOYSA-N 0.000 description 1
- ZRQATMNXTKBEOI-UHFFFAOYSA-N 1-(4-fluorophenyl)-2-[1-[3-(5-methoxy-1h-indol-3-yl)propyl]pyrrolidin-3-yl]ethanone Chemical compound C12=CC(OC)=CC=C2NC=C1CCCN(C1)CCC1CC(=O)C1=CC=C(F)C=C1 ZRQATMNXTKBEOI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- HASQSJVUSICPPG-UHFFFAOYSA-N 2-(5-methoxy-1-methylindol-3-yl)ethanol Chemical compound COC1=CC=C2N(C)C=C(CCO)C2=C1 HASQSJVUSICPPG-UHFFFAOYSA-N 0.000 description 1
- JQYYUWHWGCJWTN-UHFFFAOYSA-N 2-ethoxyoxolane Chemical compound CCOC1CCCO1 JQYYUWHWGCJWTN-UHFFFAOYSA-N 0.000 description 1
- XTDKZSUYCXHXJM-UHFFFAOYSA-N 2-methoxyoxane Chemical compound COC1CCCCO1 XTDKZSUYCXHXJM-UHFFFAOYSA-N 0.000 description 1
- OKAMTPRCXVGTND-UHFFFAOYSA-N 2-methoxyoxolane Chemical compound COC1CCCO1 OKAMTPRCXVGTND-UHFFFAOYSA-N 0.000 description 1
- XBSJNZDZMZGLBF-UHFFFAOYSA-N 3-(3-bromopropyl)-5-methoxy-1-methylindole Chemical compound COC1=CC=C2N(C)C=C(CCCBr)C2=C1 XBSJNZDZMZGLBF-UHFFFAOYSA-N 0.000 description 1
- AGRBFVDKFBYUNR-UHFFFAOYSA-N 3-(3-bromopropyl)-5-methoxy-1h-indole Chemical compound COC1=CC=C2NC=C(CCCBr)C2=C1 AGRBFVDKFBYUNR-UHFFFAOYSA-N 0.000 description 1
- SUJRVGZNRZQMLS-UHFFFAOYSA-N 3-(5-methoxy-1-methylindol-3-yl)propan-1-ol Chemical compound COC1=CC=C2N(C)C=C(CCCO)C2=C1 SUJRVGZNRZQMLS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QLWKTGDEPLRFAT-UHFFFAOYSA-N 5-Methoxytryptophol Chemical compound COC1=CC=C2NC=C(CCO)C2=C1 QLWKTGDEPLRFAT-UHFFFAOYSA-N 0.000 description 1
- UKHRGUWGMSYUFE-UHFFFAOYSA-N 6-fluoro-3-(pyrrolidin-3-ylmethyl)-1,2-benzoxazole Chemical compound N=1OC2=CC(F)=CC=C2C=1CC1CCNC1 UKHRGUWGMSYUFE-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 101150049660 DRD2 gene Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 150000008316 benzisoxazoles Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000002473 indoazoles Chemical class 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- HHUXMVSOOZIODW-UHFFFAOYSA-N methyl 2-(5-methoxy-1-methylindol-3-yl)acetate Chemical compound C1=C(OC)C=C2C(CC(=O)OC)=CN(C)C2=C1 HHUXMVSOOZIODW-UHFFFAOYSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 108010085082 sigma receptors Proteins 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9506663A FR2735129B1 (fr) | 1995-06-07 | 1995-06-07 | Nouveaux derives de l'indole, de l'indazole et du benzisoxazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO962360D0 NO962360D0 (no) | 1996-06-06 |
| NO962360L NO962360L (no) | 1996-12-09 |
| NO309090B1 true NO309090B1 (no) | 2000-12-11 |
Family
ID=9479672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO962360A NO309090B1 (no) | 1995-06-07 | 1996-06-06 | Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5703070A (es) |
| EP (1) | EP0747379B1 (es) |
| JP (1) | JPH08333362A (es) |
| CN (1) | CN1060772C (es) |
| AT (1) | ATE183183T1 (es) |
| AU (1) | AU702285B2 (es) |
| CA (1) | CA2178302C (es) |
| DE (1) | DE69603667T2 (es) |
| DK (1) | DK0747379T3 (es) |
| ES (1) | ES2137638T3 (es) |
| FR (1) | FR2735129B1 (es) |
| GR (1) | GR3031051T3 (es) |
| NO (1) | NO309090B1 (es) |
| NZ (1) | NZ286756A (es) |
| ZA (1) | ZA964842B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6187774B1 (en) * | 1996-03-04 | 2001-02-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and pharmaceutical applications thereof |
| GB9718712D0 (en) * | 1997-09-03 | 1997-11-12 | Merck Sharp & Dohme | Theraputic Agents |
| GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB9805716D0 (en) * | 1998-03-17 | 1998-05-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB9815317D0 (en) * | 1998-07-15 | 1998-09-16 | Merck Sharp & Dohme | Therapeutic agents |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| RU2269523C2 (ru) * | 2000-04-28 | 2006-02-10 | Акадиа Фармасьютикалз, Инк. | Мускариновые агонисты |
| CN1668587A (zh) | 2002-07-19 | 2005-09-14 | 明治乳业株式会社 | 吲哚衍生物及含吲哚衍生物的医药品 |
| WO2009076404A1 (en) * | 2007-12-10 | 2009-06-18 | Epix Delaware, Inc. | Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor |
| WO2009076512A1 (en) | 2007-12-11 | 2009-06-18 | Epix Delaware, Inc. | Carboxamidξ compounds and their use as chemokine receptor agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2708913A1 (de) * | 1976-03-04 | 1977-09-08 | Hoechst Ag | Benzoylpiperidyalkyl-indole und verwandte verbindungen |
| JPH0615529B2 (ja) * | 1985-04-01 | 1994-03-02 | エーザイ株式会社 | 新規ピペリジン誘導体 |
| US4980365A (en) * | 1987-07-13 | 1990-12-25 | Hoechst-Roussel Pharmaceuticals Inc. | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents |
| US5030639A (en) * | 1987-07-13 | 1991-07-09 | Hoechst-Roussel Pharmaceuticals Inc. | N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents |
| FR2644786B1 (fr) * | 1989-03-21 | 1993-12-31 | Adir Cie | Nouveaux derives fluoro-4 benzoiques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| FR2654104B1 (fr) * | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5145845A (en) * | 1991-05-14 | 1992-09-08 | Warner-Lambert Co. | Substituted 2-carboxylindoles having pharmaceutical activity |
| FR2701026B1 (fr) * | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| FR2716680B1 (fr) * | 1994-02-25 | 1996-04-05 | Adir | Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
-
1995
- 1995-06-07 FR FR9506663A patent/FR2735129B1/fr not_active Expired - Fee Related
-
1996
- 1996-06-04 JP JP8141436A patent/JPH08333362A/ja active Pending
- 1996-06-05 CA CA002178302A patent/CA2178302C/fr not_active Expired - Fee Related
- 1996-06-05 CN CN96107985A patent/CN1060772C/zh not_active Expired - Fee Related
- 1996-06-05 AU AU54735/96A patent/AU702285B2/en not_active Ceased
- 1996-06-06 DK DK96401208T patent/DK0747379T3/da active
- 1996-06-06 EP EP96401208A patent/EP0747379B1/fr not_active Expired - Lifetime
- 1996-06-06 US US08/663,464 patent/US5703070A/en not_active Expired - Fee Related
- 1996-06-06 NO NO962360A patent/NO309090B1/no not_active IP Right Cessation
- 1996-06-06 ES ES96401208T patent/ES2137638T3/es not_active Expired - Lifetime
- 1996-06-06 AT AT96401208T patent/ATE183183T1/de not_active IP Right Cessation
- 1996-06-06 NZ NZ286756A patent/NZ286756A/xx unknown
- 1996-06-06 DE DE69603667T patent/DE69603667T2/de not_active Expired - Fee Related
- 1996-06-07 ZA ZA964842A patent/ZA964842B/xx unknown
-
1999
- 1999-08-20 GR GR990402129T patent/GR3031051T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE183183T1 (de) | 1999-08-15 |
| CN1143642A (zh) | 1997-02-26 |
| CA2178302C (fr) | 2002-02-26 |
| DK0747379T3 (da) | 2000-01-31 |
| ES2137638T3 (es) | 1999-12-16 |
| FR2735129A1 (fr) | 1996-12-13 |
| EP0747379A1 (fr) | 1996-12-11 |
| CA2178302A1 (fr) | 1996-12-08 |
| AU702285B2 (en) | 1999-02-18 |
| DE69603667T2 (de) | 2000-03-09 |
| US5703070A (en) | 1997-12-30 |
| EP0747379B1 (fr) | 1999-08-11 |
| FR2735129B1 (fr) | 1997-07-11 |
| GR3031051T3 (en) | 1999-12-31 |
| NO962360D0 (no) | 1996-06-06 |
| NO962360L (no) | 1996-12-09 |
| ZA964842B (en) | 1997-01-07 |
| NZ286756A (en) | 1997-08-22 |
| JPH08333362A (ja) | 1996-12-17 |
| DE69603667D1 (de) | 1999-09-16 |
| CN1060772C (zh) | 2001-01-17 |
| AU5473596A (en) | 1996-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0745598B1 (fr) | Nouveaux composés de la pipérazine, de la pipéridine et de la 1,2,5,6-tétra-hydropyridine, leur procédé de préparation et les compositions pharmaceutiques les contenant | |
| DK174161B1 (da) | Anellerede indolderivater, fremgangsmåde til deres fremstilling og fremgangsmåde til fremstilling af farmaceutisk præparat indeholdende dem | |
| CA2207835C (fr) | Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| JPH03188077A (ja) | 新規なベンズイソキサゾール誘導体及び該誘導体を含有する製剤組成物 | |
| CN104995191A (zh) | 三环喹啉和喹喔啉衍生物 | |
| SK2492002A3 (en) | Phenylpiperazine derivatives, process for their preparation and pharmaceutical composition comprising the same | |
| NO309090B1 (no) | Nye indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem | |
| US5665722A (en) | Benzofuran derivatives as D4 receptor antagonists | |
| JP2959987B2 (ja) | 新規なベンゾジオキサン化合物、それらの製造方法およびそれらを含有する医薬組成物 | |
| CN1110496C (zh) | 四氢γ－咔啉类化合物 | |
| KR101386387B1 (ko) | 트랜스-1-((1ｒ,3ｓ)-6-클로로-3-페닐인단-1-일)-3,3-디메틸피페라진의 결정성 염기 | |
| DE69829317T2 (de) | Tetrahydrobenzindol-derivate | |
| FR2731708A1 (fr) | Derives de piperidine, leur procede de preparation et leur application en therapeutique | |
| CN101778820A (zh) | 作为5-ht2a和d3受体双重调节剂的苯甲酰基-哌啶衍生物 | |
| Schaus et al. | Aporphines as antagonists of dopamine D-1 receptors | |
| HU204517B (en) | Process for producing new 1,4-benzoxazine derivatives and pharmaceutical compositions containing them | |
| EP2907806A1 (en) | New compounds as selective PDE4D inhibitors | |
| WO1997032848A1 (fr) | Composes heterocycliques fusionnes et leurs applications pharmaceutiques | |
| ZA200304267B (en) | 8-{4-[3-(5-Fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl]-2-methyl-4H-benzo[1,4]oxazin-3-onmesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site. | |
| HU191086B (en) | Process for preparing 1-/3-/6-fluoro-1,2benzisoxazol-3-yl/-propyl/-4-hydroxy-4-phenyl-piperidines | |
| EP0765323B1 (en) | 4-(6-fluoro-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety | |
| FI63578B (fi) | Analogifoerfarande foer framstaellning av nya farmakologiskt verksamma 1,3,4,14b-tetrahydro-2h,10h-pyrazino(1,2-a)pyrrolo(2,1-c)(1,4)bensodiazepiner | |
| EP1192152A1 (fr) | Nouveaux derives benzodioxanne imidazolines fluores, leur preparation et leurs applications en therapeutique | |
| JP3185222B2 (ja) | チオフェン化合物およびその医薬用途 | |
| SK2982000A3 (en) | Piperidinylmethyloxazolidinone derivative, process for its preparation, use thereof and pharmaceutical composition containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |